Three Vanderbilt technologies receive patent protection in November

Three Vanderbilt technologies received US patent protection in the month of November. One invention includes a compound that targets positive allosteric modulation of the mGlu5 receptor for the treatment of neurological and psychiatric disorders. It was developed at Vanderbilt Center for Neuroscience Drug Discovery which is led by Vanderbilt neuroscientist P. Jeffrey Conn.

Also earning patent protection was a optical sensor that can detect chemical, biological, and explosive compounds. It was developed by Vanderbilt researchers Richard Haglund, David Cliffel, and David Wright, in collaboration with outside parties.

The final technology earning patent protection were a set of isolated nucleic acids that can be used to generate a mouse model of male infertility, for drug discovery screens, and for therapeutic treatment of fertility-related conditions. It was developed by Marie-Claire Orgebin-Crist and Robert Matusic of Vanderbilt, as well as an external researcher.

 

 

8,592,422

 

Bicyclic triazole and pyrazole lactams as allosteric modulators of mGluR5 receptors

 

8,586,371

 

Optical sensors including surface modified phase-change materials for detection of chemical, biological and explosive compounds

 

8,580,941

 

Epididymal lipocalin gene and uses thereof

 

Featured Video

Vanderbilt Patent Activity

View Vanderbilt University Patents

CTTC on Twitter